Global Lung Cancer Vaccine Market & Pipeline Insight 2015

Description: Lung cancer incidences are rapidly increasing and various therapeutics have been introduced in global market to provide better care to patients. Surgery and radiation therapy are not preferred for lung cancer treatment due to which they have small global market size. Chemotherapeutics and targeted therapeutics for lung cancer treatment are major market contender in global market with wide acceptance levels among oncologists and patients. Chemotherapeutics have life threatening side effects while targeted therapeutics available in markets are quite effective therapeutics but they are unable to reduce the present lung cancer mortality rates. These drawbacks are not expected to be associated with lung cancer vaccines which will help in generating significant revenues and increased penetration across the globe.

Identification of novel targets for lung cancer vaccine development is underway by pharmaceutical companies to provide efficient medical care to patients. Many mechanisms and tumour antigen has been identified for the development of novel lung cancer vaccines. Different lung cancer vaccines will help the patients in deciding better therapeutic options and generate significant revenues for pharmaceutical companies. Pharmacological effects provided by these novel lung cancer vaccine is expected to help the lung cancer patients across the globe.

Melanoma associated antigen 3 (MAGE-3) is target of various cancer vaccines for therapeutic treatment of lung cancer. This antigen is absent in normal cell, while it is abundantly found in cancerous cells making it a suitable candidate for developing lung cancer vaccine targeting different stages of cancer progression. These lung cancer vaccines are able to identify different levels of MAGE-3 leading to their correct identification. As a result, cancer vaccine targeting this antigen is expected to have minimized side effects because it is absent in normal cell. This fact also shows that relapse may not occur due to eradication of all existing cancerous cells from the body.

Lung cancer vaccine is formulated by incorporating MAGE-3 antigen as source of activation for immune cells. This vaccine consists of fusion between human MAGE-3 antigen and protein D from Haemophilus influenzae. When it is injected inside the body it causes the immune system to get activated and identify this formulation as external entity. This causes the memory cells to search for any external substances in body having signature sequences like vaccines. As a result, cancerous cells present in the body are identified as external entity and selectively eliminated to prevent the cancer progression.

Lung cancer vaccines are expected to become a major tool in lung cancer treatment in coming years due to superior pharmacological performance. Prophylactic lung cancer vaccines are needed to be developed and thoroughly investigated in clinical trials. Many innovative lung cancer vaccines are under various phases of clinical trials effective medical treatment. Significant clinical data generated has given encouragement to oncologists and pharmaceutical companies to investigate different forms of lung cancer vaccine. These vaccines are under investigation, once high safety and efficacy levels are obtained then it would be easy to apply for the marketing approval across the globe in various countries.

“Global Lung Cancer Vaccine Market & Pipeline Insight 2015” Report Highlights:
- Introduction to Lung Cancer Vaccine
- Global Lung Cancer Vaccine Market Analysis
- Global Lung Cancer Vaccine Pipeline by Company & Phase
- Global Lung Cancer Vaccine Pipeline: 29 Vaccines
- Majority Lung Cancer Vaccines in Phase-II: 8 Vaccines
- Marketed Lung Cancer Vaccines: 3 ( BV NSCLC 001, Mycidac-C & Vaxira)
- Personalized Cancer Vaccines: Progress & Possibilities
- Lung Cancer Vaccine Mechanism

Contents: 1. Introduction to Cancer Vaccines
  2. Cancer Vaccines: Mechanism & Innovations
     2.1 Idiotype Cancer Vaccine Mechanism
     2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Introduction Global Lung Cancer Vaccine

4. Mechanism of Lung Cancer Vaccines

5. Global Lung Cancer Vaccine Market Outlook
5.1 Current Market Scenario
5.2 Global Lung Cancer Vaccines Pipeline Overview

6. Global Lung Cancer Market Dynamics
6.1 Favorable Market Parameters
6.2 Market & Commercialization Challenges

7. Global Lung Cancer Vaccine Market Future Prospects

8. Global Lung Cancer Vaccine Pipeline by Company & Phase
8.1 Preclinical
8.2 Clinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III

9. Marketed Lung Cancer Vaccine Clinical Insight
9.1 BV NSCLC 001
9.2 Mycidac-C™
9.3 Vaxira®

10. Suspended & Discontinued Lung Cancer Vaccines Pipeline by Company & Phase
10.1 No Development Reported
10.2 Discontinued

11. Competitive Landscape
11.1 Boehringer Ingelheim
11.2 CureVac
11.3 Eli Lily
11.4 Galaxo
11.5 ImClone Systems
11.6 Merck
11.7 Ono Pharmaceutical
11.8 Oncothyreon Incorporation

List of Figures:

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Functions of Lungs
Figure 3-2: Factors Responsible for Increasing Lung Cancer Incidences
Figure 4-1: Type of Lung Cancer
Figure 4-2: Types of Lung Cancer Treatment
Figure 4-3: Mechanism of MAGE-3 Lung Cancer Vaccine
Figure 4-4: Mechanism of p53 Lung Cancer Vaccine
Figure 4-5: Mechanism of NY-ESO-1 Lung Cancer Vaccine
Figure 5-1: Global Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-2: Global Lung Cancer Vaccines Pipeline (Number), 2015
Figure 5-3: No Development Reported in Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-4: No Development Reported in Lung Cancer Vaccines Pipeline (Number), 2015
Figure 5-5: Discontinued Lung Cancer Vaccines Pipeline (%), 2015
Figure 5-6: Discontinued Lung Cancer Vaccines Pipeline (Number), 2015
Figure 6-1: Drivers for Lung Cancer Vaccines
Figure 6-2: Market & Commercialization Challenges

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3100997/](http://www.researchandmarkets.com/reports/3100997/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Global Lung Cancer Vaccine Market &amp; Pipeline Insight 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3100997/">http://www.researchandmarkets.com/reports/3100997/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCPLDZ77</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 1200</td>
</tr>
<tr>
<td>CD-ROM:</td>
<td>USD 1500 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 1800 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 3000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Last Name:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Email Address: *</td>
<td>________________________________</td>
</tr>
<tr>
<td>Job Title:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Organisation:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Address:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>City:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>________________________________</td>
</tr>
<tr>
<td>Country:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Phone Number:</td>
<td>_____________________________________________</td>
</tr>
<tr>
<td>Fax Number:</td>
<td>_____________________________________________</td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World